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Abstract 
Background: The TNM staging system is far from perfect in predicting the survival of individual cancer patients 
because only the gross anatomy is considered. The survival rates of the patients who have the same TNM stage 
disease vary across a wide spectrum. This study aimed to develop a nomogram that incorporates other clinicopatho-
logic factors for predicting the overall survival (OS) of non-metastatic nasopharyngeal carcinoma (NPC) patients after 
curative treatments.
Methods: We retrospectively collected the clinical data of 1520 NPC patients who were diagnosed histologically 
between November 2000 and September 2003. The clinical data of a separate cohort of 464 patients who received 
intensity-modulated radiation therapy (IMRT) between 2001 and 2010 were also retrieved to examine the extensibil-
ity of the model. Cox regression analysis was used to identify the prognostic factors for building the nomogram. The 
predictive accuracy and discriminative ability were measured using the concordance index (c-index).
Results: We identified and incorporated 12 independent clinical factors into the nomogram. The calibration curves 
showed that the prediction of OS was in good agreement with the actual observation in the internal validation set 
and IMRT cohort. The c-index of the nomogram was statistically higher than that of the 7th edition TNM staging sys-
tem for predicting the survival in both the primary cohort (0.69 vs. 0.62) and the IMRT cohort (0.67 vs. 0.63).
Conclusion: We developed and validated a novel nomogram that outperformed the TNM staging system in predict-
ing the OS of non-metastatic NPC patients who underwent curative therapy.
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Background
Nasopharyngeal carcinoma (NPC) is relatively common 
among patients living in the Far East and their descend-
ants who have migrated abroad [1, 2]. NPC in these 
populations is associated with Epstein–Barr virus (EBV) 
infection, which is rare in NPC patients in other parts 
of the world [3]. EBV-associated NPC has an increased 
tendency to metastasize to regional lymph nodes and dis-
tant sites. Radiotherapy remains the backbone of care in 
non-metastatic NPC patients, along with various com-
binations with chemotherapy, including induction, con-
comitant, and adjuvant chemotherapy [4].
To date, the American Joint Committee on Cancer 
(AJCC) TNM classification has been the most widely 
used staging system to estimate the prognosis and guide 
treatment options [5]. However, the TNM staging system 
is far from perfect because it only considers the tumor 
size and extension (T stage) and node involvement (N 
stage) without considering other factors with prognos-
tic values, such as clinicopathologic factors, treatment-
related factors, and tumor markers. In addition, the 
patient survival is significantly altered after curative ther-
apy, such as surgery and radiotherapy. Therefore, a more 
accurate prediction of the survival is required in clinical 
practice.
In recent years, a novel prognostic model, called a 
nomogram, has proved a reliable model for cancer 
prognosis prediction [6–8]. Nomograms incorporate 
assessable variables through weighing their respective 
significance to the survival and function as a simple tool 
for individual survival prediction [9]. However, no nomo-
grams have been developed for NPC. Therefore, based on 
a large cohort in our center, we aimed to establish a nom-
ogram for individual survival prediction of NPC patients 
without distant metastasis who had undergone curative 
therapy. In addition, a cohort of patients who received 
intensity-modulated radiation therapy (IMRT) was also 
included for validation to test whether this nomogram 
could be applied to predict survival of these patients.
Patients and methods
Patient selection and data processing
Patients with histologically proven NPC treated between 
November 2000 and September 2003 at Sun Yat-sen Uni-
versity Cancer Center were examined. The patients with 
AJCC stage I–IVb NPC who had undergone curative 
treatments (including radiotherapy alone and radiother-
apy in combination with either adjuvant chemotherapy 
or neoadjuvant chemotherapy or both) were included. 
An independent cohort of patients who underwent 
IMRT at the same institution between February 2001 and 
August 2010 was also included. Patients who had distant 
metastasis or missing data on important variables were 
excluded. Ethical approval was obtained from our center 
through the Institutional Review Board.
Clinical data were retrieved, including the age; sex; his-
tory of smoking and alcohol consumption; pathologic 
data [histological type and pathologic tumor (T), node 
(N), and metastasis (M) statuses]; treatment-related fac-
tors (radiation dose and access to neoadjuvant, con-
comitant, or adjuvant chemotherapy); and serological 
factors [hemoglobin count, platelet count, neutrophil 
count, lymphocyte count, neutrophil to lymphocyte ratio 
(NLR), titers of immunoglobulin A against Epstein–Barr 
virus viral capsid antigen (VCA-IgA), immunoglobulin A 
against Epstein–Barr virus viral early antigen (EA-IgA), 
and anti-DNase, and serum levels of lactate dehydroge-
nase (LDH) and alkaline phosphatase (ALP)].
Follow-up data for all patients were obtained from their 
most recent medical review, which consisted of sched-
uled clinical examination and assessment of chest X-ray 
photograms, chest or abdominal computed tomography 
scans, and head and neck magnetic resonance imag-
ing every 3 months during the first 2 years after primary 
treatment and every 6  months thereafter, as well as the 
survival status every 3  months, which was evaluated by 
the follow-up team. The last follow-up was carried out in 
October 2014. Clinical staging was performed according 
to the Union for International Cancer Control (UICC)/
American Joint Committee on Cancer (AJCC) TNM 
staging system (2009 version).
Continuous variables were transformed into categorical 
variables, and the cutoffs of all variables were recognized 
with the largest χ2 value in the log-rank test using a Cut-
Point Optimization Tool (X-Tile, Yale University, New 
Haven, CT, USA) [10]. The normal range of body mass 
index (BMI) was set at 20–26 kg/m2. The cutoff values for 
other variables were derived using X-Tile, and they were 
discussed and confirmed by clinical expertise as follows: 
age (50 years), hemoglobin (150 g/L), NLR (3.5), platelet 
count (300 × 109/L), ALP level (90 U/L), VCA-IgA titer 
(1:1280), EA-IgA titer [0, (negative vs. positive)], and 
anti-DNase titer (50%).
Construction and validation of the nomogram
Statistical analyses to identify independent prognos-
tic factors were conducted with SPSS 17.0 for Windows 
(SPSS, Chicago, IL, USA). Considering the large sam-
ple size of this cohort and the importance of independ-
ent validation, we adopted a data-splitting method using 
Rv.Uniform function in SPSS to randomly assign 80% of 
the patients to the training set for nomogram construc-
tion and 20% to the internal validation set. Overall sur-
vival (OS) was calculated from the date of diagnosis. 
The OS curves were generated using the Kaplan–Meier 
method and were compared using the log-rank test. 
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Covariates achieving significance at a level of P  <  0.05 
were entered into the Cox regression model for multivar-
iate analyses. Based on the results from multivariate anal-
ysis, a nomogram was formulated using R2.14.1 (http://
www.r-project.org/) with the survival and rms package, 
which was based on the theory by Harrel et  al. [11]. A 
final model was selected using a backward stepdown pro-
cess, which incorporated Akaike’s information criterion 
as the stopping rule [12].
The derived scores were divided into the 25th, 50th, 
75th, and 100th percentile to subgroup the patients. Cal-
ibration of the nomogram for the 1-, 3-, and 5-year OS 
was performed by comparing the median predicted OS 
with the actual OS from observed Kaplan–Meier esti-
mates. The model performance for predicting the out-
come was evaluated by calculating the concordance index 
(c-index) [13]. The value of the c-index ranged from 0.5 to 
1.0, which indicates random chance to a perfect ability to 
correctly discriminate between the outcome and model.
Performance of the nomogram beyond the TNM staging 
system
We sought to evaluate the independent discrimination 
ability of the nomogram beyond the standard TNM stag-
ing. Kaplan–Meier OS curves of patient subgroups were 
delineated.
Results
Clinicopathologic characteristics of patients in the primary 
cohort
A total of 1520 patients with stage I–IVb NPC who 
had undergone at least radiotherapy in the primary 
cohort were eligible for final analysis, with 1036 deaths 
in a median follow-up of 86.6  months (range 1.4–
115.0  months). The predominant histological type was 
World Health Organization (WHO) type III. Most of the 
included patients received conventional radiotherapy. 
Of the 1520 patients, 1216 (80%) were assigned to the 
training set, and 304 (20%) to the internal validation set. 
An independent cohort of 464 patients who underwent 
IMRT was selected, with 376 events in a median follow-
up of 86.1 months (range 29.2–133.0 months). The clin-
icopathologic features of patients in the training set, 
internal validation set, and IMRT cohort are summarized 
in Table 1.
Independent prognostic factors in the training set
The data from the training set were used to identify prog-
nostic factors and build the model. The results of the uni-
variate analysis are listed in Table  2. Male gender, over 
50  years old, smokers, drinkers, increased NLR (≥3.5), 
increased platelet count (≥300 × 109/L), increased ALP 
level (≥90 U/L), positive EA-IgA, high anti-DNase titer 
(>50%), receiving no neoadjuvant, concomitant, or adju-
vant chemotherapy, and high radiation dose (>75  Gy) 
were all associated with poor prognosis. Baseline anemia 
and a high titer of VCA-IgA were probably associated 
with poor prognosis, but the differences were not signifi-
cant. Both the pathologic T and N stages had a signifi-
cant impact on OS; there was an increased risk for deaths 
as the stage increased. The BMI and LDH were divided 
into three categories. A high BMI indicated a favorable 
survival outcome, whereas a reverse trend was revealed 
for the LDH level. WHO type III was the predominant 
histological type and associated with the best prognosis 
among all three types.
Variables considered significant in the univariate analy-
ses were entered in the Cox multivariate analysis. A total 
of 12 variables, including sex, age, T stage, N stage, BMI, 
NLR, radiation dose, assess to neoadjuvant or concomi-
tant chemotherapy, EA-IgA titer, and serum LDH and 
ALP levels were proved independent in the multivariate 
Cox regression model and were incorporated in the nom-
ogram according to the algorithm (Table 2).
Prognostic nomogram for OS prediction
Using the data of patients in the training set, a nomo-
gram was constructed for OS prediction (Fig. 1). Longer 
lines indicate greater prognostic impact of specific vari-
ables, and larger points in the nomogram indicate shorter 
OS. The N stage had the greatest impact on OS, which 
was followed by the T stage, LDH level, and age. Sub-
sequently, the BMI, NLR, and radiation dose were also 
found to be important. Furthermore, other independent 
prognostic factors provided additional prediction value.
Each subtype within the above variables was assigned a 
score on the point scale. By adding up the total score and 
locating it on the total point scale, we could easily draw a 
straight line down to determine the estimated probabil-
ity of survival at each time point. The total scores ranged 
from 6 to 39. By dividing the range into five equal parts, 
we determined five risk subgroups of patients (scoring 
0–12, 13–18, 19–24, 25–31, and ≥32).
Validation of the nomogram
The data from the internal validation set were used to 
validate the model. The calibration plot based on the data 
from the internal validation set for the probability of OS 
at 1, 3, and 5  years demonstrated excellent agreement 
between the prediction according to the nomogram and 
actual observation (Fig.  2a). However, the predicted OS 
was slightly underestimated in the IMRT cohort (Fig. 2b). 
In addition, the Harrel’s c-index of the established nom-
ogram to predict the OS of all patients in the primary 
cohort (combining the training set and the internal vali-
dation set) was significantly higher than that of the AJCC 
Page 4 of 8Liang et al. Chin J Cancer  (2016) 35:98 
TNM staging system (0.69 [95% confidence interval 
{CI}, 0.67–0.71] vs. 0.62 [95% CI, 0.60–0.64], P = 0.003). 
With respect to OS prediction for the IMRT cohort, the 
c-index of the nomogram was also numerically higher 
than that of the TNM staging system (0.67 [95% CI, 0.62–
0.72] vs. 0.63 [95% CI, 0.58–0.78], P = 0.631).
Performance of the nomogram in predicting the cancer 
death risk of patients
We scored the cancer death risk of every patient and 
classified the patients into five subgroups with distinct 
prognoses. The 5 year OS rates of the five risk subgroups 
with risk scores of 0–12, 13–18, 19–24, 25–31, and ≥32 
were 90, 82, 68, 54, and 40%, respectively. When patients 
in the primary cohort were grouped according to their 
Table 1 Demographic and  clinicopathologic characteris-
tics of non-metastatic nasopharyngeal carcinoma patients 
in the training set, internal validation set, and IMRT cohort
Variable Primary cohort [cases (%)] IMRT cohort 
[cases (%)]
Total Training set Validation set
Total 1520 1216 304 464
Sex
 Male 1161 (76.4) 922 (75.8) 239 (78.6) 361 (77.8)
 Female 359 (23.6) 294 (24.2) 65 (21.4) 103 (22.2)
Age (years)
 <50 977 (64.3) 769 (63.2) 208 (68.4) 345 (74.4)
 ≥50 543 (35.7) 447 (36.8) 96 (31.6) 119 (25.6)
Smoking history
 No 789 (51.9) 630 (51.8) 159 (52.3) 271 (58.4)
 Yes 731 (48.1) 586 (48.2) 145 (47.7) 193 (41.6)
Alcohol consumption
 No 1282 (84.3) 1030 (84.7) 252 (82.9) 387 (83.4)
 Yes 238 (15.7) 186 (15.3) 52 (17.1) 77 (16.6)
BMI (kg/m2)
 >26 210 (13.8) 174 (14.3) 36 (11.8) 150 (32.3)
 20–26 949 (62.4) 755 (62.1) 194 (63.8) 312 (67.2)
 <20 361 (23.8) 287 (23.6) 74 (24.3) 2 (0.4)
Hemoglobin level (g/L)
 >150 498 (32.8) 399 (32.8) 99 (32.6) 186 (40.1)
 ≤150 1022 (67.2) 817 (67.2) 205 (67.4) 278 (59.9)
NLR
 <3.5 1129 (74.3) 906 (74.5) 223 (73.4) 384 (82.8)
 ≥3.5 391 (25.7) 310 (25.5) 81 (26.6) 80 (17.2)
Platelet count (×109/L)
 <300 1251 (82.3) 1000 (82.2) 251 (82.6) 408 (87.9)
 ≥300 269 (17.7) 216 (17.8) 53 (17.4) 56 (12.1)
LDH level (U/L)
 <190 897 (59.0) 717 (59.0) 180 (59.2) 352 (75.9)
 190–240 399 (26.3) 315 (25.9) 84 (27.6) 80 (17.2)
 >240 224 (14.7) 184 (15.1) 40 (13.2) 32 (6.9)
ALP level (U/L)
 <90 1227 (80.7) 978 (80.4) 249 (81.9) 401 (86.4)
 ≥90 293 (19.3) 238 (19.6) 55 (18.1) 63 (13.6)
Histological type
 WHO I 6 (0.4) 5 (0.4) 1 (0.3) 1 (0.2)
 WHO II 102 (6.7) 78 (6.4) 24 (7.9) 41 (8.8)
 WHO III 1412 (92.9) 1133 (93.2) 279 (91.8) 422 (90.9)
T stage
 T1 262 (17.2) 198 (16.3) 64 (21.1) 86 (18.5)
 T2 746 (49.1) 603 (49.6) 143 (47.0) 119 (25.6)
 T3 267 (17.6) 213 (17.5) 54 (17.8) 191 (41.2)
 T4 245 (16.1) 202 (16.6) 43 (14.1) 68 (14.7)
N stage
 N0 419 (27.6) 337 (27.7) 82 (27.0) 116 (25.0)
 N1 642 (42.2) 510 (41.9) 132 (43.4) 193 (41.6)
 N2 408 (26.8) 326 (26.8) 82 (27.0) 144 (31.0)
IMRT intensity-modulated radiation therapy; BMI body mass index; NLR 
neutrophil–lymphocyte ratio; LDH lactate dehydrogenase; ALP alkaline 
phosphatase; WHO World Health Organization; VCA-IgA immunoglobulin A 
against Epstein–Barr virus viral capsid antigen; EA-IgA immunoglobulin A against 
Epstein–Barr virus viral early antigen
a The data of 38 patients were missing
Table 1 continued
Variable Primary cohort [cases (%)] IMRT cohort 
[cases (%)]
Total Training set Validation set
 N3 51 (3.4) 43 (3.5) 8 (2.6) 11 (2.4)
TNM stage
 I 79 (5.2) 60 (4.9) 19 (6.3) 43 (9.3)
 II 638 (42.0) 511 (42.0) 127 (41.8) 113 (24.4)
 III 515 (33.9) 408 (33.6) 107 (35.2) 231 (49.8)
 IV 288 (18.9) 237 (19.5) 51 (16.8) 77 (16.6)
VCA-IgA titer
 <1:1280 1275 (83.9) 1013 (83.3) 262 (86.2) 420 (90.5)
 ≥1:1280 245 (16.1) 203 (16.7) 42 (13.8) 44 (9.5)
EA-IgA
 Negative 334 (22.0) 272 (22.4) 62 (20.4) 127 (27.4)
 >0 1186 (78.0) 944 (77.6) 242 (79.6) 337 (72.6)
Anti-DNase (%)
 ≤50 516 (33.9) 407 (33.5) 109 (35.9) 221 (47.6)
 >50 1004 (66.1) 809 (66.5) 195 (64.1) 205 (44.2)a
Neoadjuvant chemotherapy
 Yes 997 (65.6) 800 (65.8) 197 (64.8) 304 (65.5)
 No 523 (34.4) 416 (34.2) 107 (35.2) 160 (34.5)
Concomitant chemotherapy
 Yes 1171 (77.0) 933 (76.7) 238 (78.3) 145 (31.3)
 No 349 (23.0) 283 (23.3) 66 (21.7) 319 (68.7)
Adjuvant chemotherapy
 Yes 1513 (99.5) 1210 (99.5) 303 (99.7) 445 (95.9)
 No 7 (0.5) 6 (0.5) 1 (0.3) 19 (4.1)
Radiation dose (Gy)
 ≤75 1329 (87.4) 1059 (87.1) 270 (88.8) 240 (51.7)
 >75 191 (12.6) 157 (12.9) 34 (11.2) 224 (48.3)
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respective TNM stages (I, II, III, and IV), the stratifica-
tion by risk scores resulted in significant differences in 
Kaplan–Meier OS curves for patients in each stage group, 
except for patients in stage I (Fig. 3a). As for the IMRT 
cohort, this stratification also resulted in significant dif-
ferences in OS, except for patients in stage IV (Fig. 3b).
Discussion
In the present study, we evaluated the prognostic values 
of several known predictors for survival of NPC patients. 
The association between the clinicopathologic factors and 
prognosis of NPC patients has been well established in 
previous studies [14–21] and was then confirmed in the 
present study. Notably, the serum level of LDH ranked 
third in contributing to the prognosis of NPC patients, 
which followed the N and T stages. This finding called 
attention to the importance of the baseline LDH, which 
might indicates the tumor activity and tendency for metas-
tasis in NPC patients, especially in combination with ALP 
level [22]. Based on these results, we established a nomo-
gram that combined 12 significant clinical factors to visu-
alize the prediction of the prognosis of NPC patients.
With respect to the validation methods, both internal 
validation and external validation are appropriate. How-
ever, internal validation, such as cross-validation and 
bootstrap resampling, has a theoretical probability of 
overinterpretation [9]. Therefore, external validation is 
more appropriate for examining the model applicability, 
e.g., using a data set from other institutions or a valida-
tion set by the data-splitting method from the same insti-
tution, especially when the sample size is large [7, 13]. 
In this study, we calibrated the nomogram with a valida-
tion set and an IMRT cohort from the same institution 
that were independent from the training set. First, the 
high level of agreement between the expected and actual 
observed OS in the splitting internal validation set dem-
onstrated the accuracy of the nomogram. In addition, 
discrimination was revealed by the significantly higher 
c-index (an index similar to the area under the receiver-
operating characteristic curves in the diagnostic test) of 
the nomogram compared with the TNM staging system. 
The distinct risk stratification of patients within the same 
stage illustrated the additional prognostic values of incor-
porating other factors.
Table 2 Cox univariate and  multivariate analyses of  prognostic factors for  the overall survival of  non-metastatic naso-
pharyngeal carcinoma patients after treatment
HR hazard ratio; CI confidence interval. Other abbreviations as in Table 1
Variable Univariate analysis Multivariate analysis
P value HR 95% CI P value
Sex 0.023 1.228 1.093–1.363 0.163
Age <0.001 1.572 1.478–1.666 <0.001
Smoking history 0.025 0.957 0.845–1.070 0.833
Alcohol consumption 0.048 1.056 0.930–1.182 0.279
BMI 0.014 1.164 1.087–1.241 0.004
Hemoglobin 0.079 Not included in the  
multivariate analysis
NLR <0.001 1.324 1.225–1.423 0.001
Platelet count 0.015 1.165 1.048–1.282 0.366
LDH level <0.001 1.332 1.273–1.391 <0.001
ALP level 0.001 1.235 1.126–1.344 0.185
Histological type 0.032 0.986 0.538–1.434 0.082
T stage <0.001 1.264 1.212–1.316 <0.001
N stage <0.001 1.457 1.399–1.515 <0.001
TNM stage <0.001 Excluded due to collinearity
VCA-IgA titer 0.099 Not included in the  
multivariate analysis
EA-IgA 0.001 1.224 1.100–1.348 0.179
Anti-DNase titer 0.019 1.155 1.022–1.288 0.43
Neoadjuvant chemotherapy <0.001 1.209 1.111–1.308 0.043
Concomitant chemotherapy 0.022 1.167 1.060–1.274 0.424
Adjuvant chemotherapy 0.035 1.747 1.238–2.256 0.37
Radiation dose 0.002 1.415 1.282–1.548 0.009
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As it conforms more to the tumor shape and mini-
mizes the toxicity to surrounding normal tissues, IMRT 
has been increasingly applied and has even replaced 
conventional radiotherapy (CRT) in recent years [23]. 
Considering that patients in the training set on which 
the nomogram was built predominantly received CRT, 
we retrieved a pure cohort that was treated with IMRT. 
An underestimation of OS was observed for the nomo-
gram. Additionally, the predictive accuracy (c-index) of 
the nomogram decreased slightly in the IMRT cohort, 
which was in contrast to that of the TNM staging system. 
This might be a result of overfit bias, which is inevitable 
when developing a nomogram. In addition, the patient 
selection periods for the primary and IMRT datasets did 
not completely overlap. To the best of our knowledge, 
the patients who underwent CRT and IMRT primar-
ily differed in their adverse events and short-term out-
comes, but they did not necessarily differ in the OS [24]. 
Moreover, the included variables have no mechanical 
association with the radiotherapy modality. Therefore, we 
cautiously concluded that this nomogram could project 
to the IMRT population according to the acceptable pre-
dictive power and accuracy.
Several previous models established for NPC also 
showed improved prognosis prediction of the TNM 
staging system by adding some functional factors [25–
27]. However, the practical use of these models was 
restricted because they only provided stratification of 
risks at a population level without offering an association 
between the individual patient and his/her correspond-
ing OS. In contrast, the nomogram we developed in this 
study could serve as both a scoring system and a visu-
alized predicting tool, which could help physicians rap-
idly match a patient with his/her expected OS through 
a simple calculation in clinical practice. In addition, this 
nomogram could assist in the clinical study design, bal-
ancing the prognostic background between different 
arms, especially for non-randomized data. This function 
shares a similar rationale with propensity score-matched 
analysis [28].
Fig. 1 Prognostic nomogram for patients with non-metastatic nasopharyngeal carcinoma (NPC). BMI body mass index; NLR neutrophil–lympho-
cyte ratio; LDH lactate dehydrogenase; ALP alkaline phosphatase; EA-IgA immunoglobulin A against Epstein–Barr virus viral early antigen
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This nomogram developed for NPC patients assists 
clinicians in many aspects. Still, there are some limi-
tations. First, the retrospective nature of the database 
might result in bias and calls for prospective validation of 
the model. Second, we have not yet validated the model 
using an external dataset from other institutes, although 
we are seeking further collaborations. Third, although 
the EBV-DNA copy number might be a strong prognos-
tic factor, we failed to incorporate it into the nomogram 
because EBV-DNA was not routinely tested in our center 
until 2007 [29].
In conclusion, we developed and validated a novel 
nomogram for non-metastatic NPC patients. This nom-
ogram provides a more accurate and precise prediction 
for the OS compared with the TNM staging system. This 
nomogram could help clinicians with decision-making 
and study design. In addition, this nomogram could be 
used to evaluate the prognosis of the IMRT population.
Fig. 2 The calibration curve for predicting overall survival (OS) of patients with non-metastatic NPC in the internal validation set (a) and intensity-
modulated radiation therapy (IMRT) cohort (b). The nomogram-predicted probability of OS is plotted on the x-axis; the actual OS is plotted on the 
y-axis
Fig. 3 Kaplan–Meier OS curves of non-metastatic NPC patients in each stage stratified by the scores of risk (0–12, 13–18, 19–24, 25–31, and ≥32) in 
the internal validation cohort (a) and IMRT cohort (b) (pooled log-rank test)
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